Quanterix Lab Earns New York State Clinical Testing Permit
Allow approval allows expanded analysis capabilities and underscores dedication to accuracy, reliability, and scientific excellence
Quanterix Company (NASDAQ: QTRX), an organization fueling scientific discovery via ultrasensitive biomarker detection, right this moment introduced the New York State Division of Well being (NYSDOH) has granted the Quanterix Accelerator Laboratory a scientific laboratory allow within the Medical Chemistry class. The allow approval expands superior biomarker analysis led by Quanterix, deepening collaborations with scientific, pharmaceutical, and analysis companions. The Quanterix Accelerator Lab is now totally CLIA-certified in all 50 states, enabling complete scientific testing and biomarker evaluation nationwide.
“Collaboration is on the core of the Quanterix Accelerator Laboratory,” stated Masoud Toloue, PhD, Chief Govt Officer of Quanterix. “Each breakthrough remedy and scientific trial begins with robust partnerships. Securing this allow reaffirms our dedication to high quality and compliance and allows us to increase our experience to a broader community of scientific and analysis companions.”
The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® expertise to ship unmatched precision in protein biomarker detection, supporting biopharmaceutical analysis, scientific testing, and customized assay growth. Licensed beneath the Medical Laboratory Enchancment Amendments (CLIA) program, the Lab has developed 100+ customized assays and supported over 264 international scientific trials throughout neurology, immunology/oncology, and infectious ailments, combining fast turnaround with devoted venture administration to speed up discovery and therapeutic innovation.
The most recent achievement in a collection of progress milestones for the Lab, the brand new allow underscores Quanterix’s dedication to assembly the very best benchmarks for accuracy, reliability, and security. As one of many nation’s largest healthcare markets, New York’s scientific testing requirements are among the many most complete within the nation, requiring labs to satisfy rigorous Medical Laboratory Analysis Program (CLEP) requirements.
Accelerator’s Simoa® NfL Laboratory Developed Check (LDT) gained approval as a part of the laboratory allowing. Authorizations for extra scientific assessments are deliberate to additional broaden the out there check menu.
Moreover, working beneath the Quanterix Accelerator Laboratory, the Lucent Diagnostics model now offers superior serum and plasma biomarker testing to the scientific and analysis group. This integration combines the Accelerator Lab’s rigor and ultra-sensitive Simoa® expertise with Lucent Diagnostics’ give attention to delivering actionable scientific insights, increasing the attain and impression of biomarker-driven discovery and diagnostics.
The publish Quanterix Lab Earns New York State Clinical Testing Permit first appeared on AI-Tech Park.
